AlzChem Group (ACT) Q1 2026 earnings summary

Executive summary

• Group revenue grew 3% year-over-year to approximately EUR 148.7 million in Q1 2026, with EBITDA rising 18% to EUR 32.3 million and EBITDA margin expanding to 21.7%.

• Profitability outpaced revenue growth, driven by high-margin Specialty Chemicals, especially in human nutrition and defense, while Basics & Intermediates declined due to weak market conditions.

• Net income after taxes increased by 23% year-over-year to EUR 18 million, reflecting scalability and disciplined cost management.

• Free float increased to nearly 75%, enhancing stock liquidity and visibility.

• Full-year 2026 forecast confirmed, with further growth momentum expected in the second half.

Financial highlights

• Q1 2026 revenue: EUR 148.7 million (+3% YoY); EBITDA: EUR 32.3 million (+18% YoY); EBITDA margin improved to 21.7% from 18.9% YoY.

• Net income rose 23% YoY to EUR 18.0 million; earnings per share increased to EUR 1.77 (+23%).

• Equity ratio improved to 42.2% by end of March 2026.

• Free cash flow remained positive despite high CapEx and lower customer grants.

• Net cash position at EUR 29.8 million at quarter-end.

Outlook and guidance

• Full-year 2026 guidance confirmed: sales expected to reach approximately EUR 600 million (+7%), EBITDA to EUR 126 million (+8%), with margin slightly increasing to 21%.

• Growth to be driven organically, especially by volume effects in Specialty Chemicals, with defense and human nutrition as key drivers.

• Basics & Intermediates segment sales expected to remain flat or decline year-over-year.

• Outlook assumes raw material price increases can be passed to customers and that geopolitical conflicts will not persist long-term.

• Geopolitical and supply chain risks remain closely monitored and are not yet factored into the forecast.